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Only a subset of hierarchically arranged, primitive humanAMLprogenitor cells can initiate the disease
in transplanted immune-deficientmice. Apublication inNatureBiotechnologyby Ishikawaet al. (2007)
describes a new animalmodel to study chemotherapy-resistant, quiescent humanAMLCD34+CD38
stem cells, which are retained in the endosteum region.Characterization of the bone marrow
(BM) microenvironment supporting
growth and survival of normal and
malignant hematopoietic stem cells
presents a major challenge. Early ob-
servations revealed that bone frac-
tures, blood that has just passed
through bone, and trauma and injury
to the endosteal milieu all provide a
nourishing stimulus to hematopoietic
marrow (Van Dyke and Harris, 1969).
The concept emerged of preferential
stem cell localization, maintenance,
and growth in specific sites within the
BM, primarily in the endosteum region
and in periarterial sites. The endosteal
microenvironment is dynamic due to
bone remodeling, resulting from oste-
oclast/osteoblast interactions and ac-
tivities, affecting hematopoietic stem
cell retention and mobilization (Kollet
et al., 2006).
The study by Ishikawa and col-
leagues (Ishikawa et al., 2007) de-
scribes a novel preclinical model to
assay human acute myeloid leukemia
(AML)-initiating cells by transplantingprimitive CD34+CD38 and more dif-
ferentiated, immature CD34+CD38+
populations sorted from patient sam-
ples into newborn NOD/SCID/IL2rgnull
immune-deficient mice. These mice
are currently the most immune-defi-
cient recipients and thus the most
permissive for human stem cell trans-
plantation and identification of serially
transplanted, long-term repopulating
leukemic stem cells (LSCs). Only a
subsetofhierarchicallyarranged,primi-
tive human AML progenitor cells can
initiate the disease in transplanted im-
mune-deficient mice (Lapidot et al.,
1994). In agreement, Ishikawa et al.
show that only the primitive CD34+
CD38 population initiates the disease
in their model. This cell population is
enriched with LSCs, which exhibit
self-renewal capacity in vivo and also
maintain the surface phenotype and
gene expression pattern observed in
the primitive fraction of leukemic cells
isolated from the original donor. In-
triguingly, applying an approach de-
veloped by Nilsson et al., the authorsCell Stem Cell 1,determined that human CD34+CD38
LSCs primarily homed to and were
retained in greater numbers in the end-
osteum region of the femur. It has been
shown previously that normal enriched
primitive murine progenitor cells pref-
erentially home to this site, while
more committed progenitors favored
homing to the central marrow (re-
viewed in Lapidot et al., 2005). Is it
a universal feature of hematopoietic
stem cells that upon transplantation
they home to and are retained in spe-
cific privileged BM sites? Are these
sites enriched with factors that regu-
late stem cells and maintain their self-
renewal and developmental potential?
The chemokine SDF-1 (CXCL12) is
a major chemotactic and survival fac-
tor for both human and murine hema-
topoietic stem cells. As shown by
Sipkins and colleagues, primitive nor-
mal murine and leukemic human cells
home to SDF-1-rich areas, such as
sinusoidal endothelium in the murine
skull flat bones and immature bone lin-
ing osteoblasts (discussed in LapidotNovember 2007 ª2007 Elsevier Inc. 483
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Previewset al., 2005). CXCL12-abundant reticu-
lar (CAR) cells in the BM were recently
identified in contact with the majority
of primitive murine hematopoietic
SLAM cells, a population highly en-
riched with BM-repopulating stem
cells (Sugiyama et al., 2006). It was
suggested by the group of Broxmeyer
that SDF-1 cleavage by CD26 ex-
pressed on hematopoietic progenitor
cells reduces their homing and en-
graftment potential (reviewed in Lapi-
dot et al., 2005). Collectively, these
studies suggest that SDF-1/CXCR4
interactions are also critical for LSC
endosteal homing and retention.
Ishikawa and colleagues also found
that in the endosteum region, primitive
CD34+CD38 human AML cells, unlike
CD34+CD38+ cells, were protected
from cytotoxic chemotherapy and
some were retained adjacent to osteo-
pontin (OPN)-expressing osteoblasts.
The authors suggest that chemother-
apy resistance is due to the quiescent
state of LSCs. Homing to the endos-
teum and quiescence of primitive mu-
rine cells are regulated by OPN, which
is degraded together with SDF-1 and
other endosteal components by oste-
oclasts, as part of stem cell mobiliza-
tion (discussed in Kollet et al., 2006).
Can the endosteal microenvironment
induce quiescence and provide pro-
tection to LSCs? Interestingly, it was
demonstrated that CXCL12 produced
by CAR cells promotes quiescence of
primitive murine SLAM cells (Su-
giyama et al., 2006). Low concentra-
tions of SDF-1 induce a G0/G1 transi-
tion and increase the survival of
immature human CD34+ cells, while
high levels of this ligand cause human
CD34+ progenitor cell quiescence and
retention in a nonmotile mode. Cycling,
normal CD34+CD38+ cells secrete low
levels of SDF-1 in an autocrine manner,
unlike the more primitive, quiescent hu-
man CD34+CD38 cells. Importantly,
cell cycle affects homing and retention
of repopulating progenitor cells (dis-
cussed in Lapidot et al., 2005), thus it
is possible that by virtue of being non-
cycling, primitive LSCs better home to
and are retained in the SDF-1-rich end-
osteum region, while approaches in-
terfering with SDF-1/CXCR4 interac-484 Cell Stem Cell 1, November 2007 ª2tions could induce LSCs to cycle,
leading to improved sensitivity to che-
motherapy treatment. However, quies-
cent AML LSCs are also present in the
circulation of patients and it is yet to be
determined whether they are more
susceptible to cell death mediated by
radio and chemotherapy.
Currently, many AML patients do
not achieve remission and the majority
relapse following chemotherapy. In
order to advance our understanding
of LSC biology and to improve clinical
protocols, a critical question needs to
be addressed: is it possible to discrim-
inate LSCs from normal stem cells?
This is the case in at least some
instances; for example, while both
normal and leukemic human CD34+
CD38 stem cells require SDF-1/
CXCR4 interactions for their homing
and repopulation of the BM in im-
mune-deficient mice, human AML
progenitors are more dependent on
SDF-1/CXCR4 signaling for their BM
retention and survival than normal
CD34+ cells (Tavor et al., 2004). In
line with this finding, CXCR4 expres-
sion is a poor prognostic marker in
AML patients (Spoo et al., 2007). Ishi-
kawa and colleagues performed a
global transcriptional profile, compar-
ing CD34+CD38 LSCs with the more
differentiated CD34+CD38+ cells, and
identified an LSC-specific expression
pattern, which includes negative regu-
lators of apoptosis, cell-cycle regula-
tors, and adhesion molecules. We
have previously demonstrated that
normal human CD34+ cell homing
and repopulation of transplanted
NOD/SCID mice requires the crosstalk
of CXCR4 signals with the interaction
of the adhesion molecule CD44 and
its ligand, hyaluronan (Avigdor et al.,
2004). Importantly, high levels of hya-
luronan were detected in the stem
cell- and SDF-1-rich human endosteal
and sinusoidal regions (Avigdor et al.,
2004). Of interest, AML CD34+ cells
express higher levels of CD44 com-
pared to normal human CD34+ pro-
genitors, including the more primitive
population of CD34+CD38 cells (Jin
et al., 2006). In contrast to its limited
effect on normal human CD34+ pro-
genitors, CD44 activation on human007 Elsevier Inc.AML CD34+ cells using a unique Ab
impaired their homing and repopula-
tion of NOD/SCID mice (Jin et al.,
2006). These and other studies imply
that normal and leukemic stem cells
differ in their dependence on the
supportive microenvironment. Finally,
based on the maintenance of the
AML phenotype and gene expression
pattern of LSCs in patients and trans-
planted mice, the authors propose
that tailor-made, patient-specific ther-
apies could be developed and tested
using their model to evaluate efficacy
and optimal therapeutic regimes for
individual treatment. These and further
questions can be studied initially using
the model developed by Ishikawa
et al., which when combined with other
preclinical immune-deficient mouse
systems will provide mechanistic in-
sights as to the similarities and differ-
ences between normal and leukemic
human stem cells and their regulation
by the microenvironment.
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